Published: October 1, 2025 at 7:30 am
TruSpine Technologies Plc has delayed the completion and publication of its audited accounts for the year to 29th March 2025 – and trading in its shares has been suspended temporarily as a result.
Based at London Gatwick, the medical device company is focused on the spinal stabilisation market. It is aiming to commercialise Cervi-LOK, a screw-free spinal stabilisation system which aims to minimise the risk of vertebral artery injury which can cause brainstem stroke or nerve root and spinal cord injury.
However, supply chain issues and external issues around testing delayed expected FDA clearance in the United States in 2022, leaving it seeking funding to see it through its FDA submission. Its CEO resigned last year.
“The company anticipates that it will be in a position to publish its final results shortly, following which trading in its shares will be restored. A further announcement will be made in due course,” it said in a notice to the London Stock Exchange.